Altimmune Inc

ALT10 Dec 2024
Healthcare
$9.56
-0.06 (-5.91%)
Lowest Today
$8.95
Highest Today
$9.95
Today’s Open
$9.56
Prev. Close
$9.64
52 Week High
$14.84
52 Week Low
$4.71
To Invest in Altimmune Inc

Altimmune Inc

Healthcare
ALT10 Dec 2024
-0.06 (-5.91%)
1M
3M
6M
1Y
5Y
Low
$8.95
Day’s Range
High
$9.95
8.95
52 Week Low
$4.71
52-Week Range
52 Week High
$14.84
4.71
1 Day
-
1 Week
+9.72%
1 month return
+31.04%
3 month return
+38.57%
6 month return
+54.07%
1 Year return
+85.48%
3 Years return
+2.6%
5 Years return
+424.18%
10 Years return
-
Institutional Holdings
BlackRock Inc
7.48
Vanguard Group Inc
7.01
Ameriprise Financial Inc
5.45
State Street Corp
4.8
TANG CAPITAL MANAGEMENT LLC
3.87
Vanguard Total Stock Mkt Idx Inv
3.52
iShares Russell 2000 ETF
2.79

Market Status

Fundamentals
Market Cap
647.95 mln
PB Ratio
4.86
PE Ratio
0
Enterprise Value
510.34 mln
Total Assets
210.64 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Organisation
Altimmune Inc
Employees
59
Industry
Biotechnology
CEO
Dr. Vipin K. Garg Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step